Prospects for better tuberculosis vaccines.
Tuberculosis remains one of the top three infectious disease killers. Treatment is long and expensive and drug resistant strains of Mycobacterium tuberculosis are already on the rise. The current vaccine, BCG, is ineffective in parts of the world where the disease is most widespread and therefore the search for a novel, more effective vaccine is paramount. In this review we discuss the current state of vaccine research, including the identification of candidate antigens and the current methods used for their evaluation.
Collins
H L
HL
Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany. collins@mpiib-berlin.mpg.de
Kaufmann
S H
SH
D000818:Animals; D001500:BCG Vaccine / Q000276:immunology / Q000592:standards; D004195:Disease Models, Animal; D006801:Humans; D014376:Tuberculosis / Q000453:epidemiology / Q000517:prevention & control*; D014613:Vaccines, Attenuated / Q000276:immunology / Q000592:standards; D019444:Vaccines, DNA / Q000276:immunology / Q000592:standards; D022223:Vaccines, Subunit / Q000276:immunology / Q000592:standards
D001500:BCG Vaccine; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA; D022223:Vaccines, Subunit